<DOC>
	<DOCNO>NCT01483014</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability imatinib neoadjuvant treatment ( pre-operatory ) patient GIST . It also evaluate potential imatinib convert tumor inoperable operable .</brief_summary>
	<brief_title>Phase Study Imatinib Mesylate Neoadjuvant Treatment Patients With Gastrointestinal Stromal Tumors ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>patient age 18 80 year diagnosis GIST previously treat Patients include protocol regardless operability ; case operable tumor , patient eligible , opinion surgeon , resection would suboptimal , disfigure functionally disable ( i.e . incomplete resection cold compromise severely quality life GI function ) Exclusion criterion : presence metastatic disease use antineoplastic treatment ( chemotherapy , immunotherapy , radiotherapy ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gastrointestinal ,</keyword>
	<keyword>stromal ,</keyword>
	<keyword>neoadjuvant ,</keyword>
	<keyword>imatinib ,</keyword>
	<keyword>mesylate ,</keyword>
	<keyword>pre-operatory</keyword>
</DOC>